<DOC>
	<DOCNO>NCT01137136</DOCNO>
	<brief_summary>Aromatase ( CYP19 ) inhibitor one major antihormonal drug breast cancer postmenopausal woman . The variation CYP19 may affect effect aromatase inhibitor . However , incidence variation CYP19 Korea know . Therefore , investigator want know incidence variation CYP19 ass effect variation CYP19 aromatase inhibitor user .</brief_summary>
	<brief_title>Aromatase ( CYP19 ) Polymorphism Between AI-responsive AI-resistant Breast Cancer Korea</brief_title>
	<detailed_description />
	<criteria>hormone receptor positiveBreast cancer patient postmenopausal woman first user aromatase inhibitor premenopausal The patient take antihormonal therapy osteoporosis patient</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>